“…Data from early uncontrolled studies of this alkylating agent suggest asimilarmodest benefit. Inonestudy, 21 patients with chronicprogressiveMS were treated with low-dose cyclophosphamide and only one had worsened, using standard clinical scoring, 1 year later compared with 14 out of 24 worsening after corticosteroid therapy (26). Morerecently, the interim results fromaNorth American multicentre trial of intravenous cyclophosphamidel ACTH, with or without 2-monthly cyclophosphamide maintenance boosters, in a 5-year, randomized, singleblind study showed a positive effect on the rate of disease progression in favour of booster therapy (27).…”